ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Oncology biotech Tyra Biosciences files for a $100 million IPO
August 23, 2021Tyra Biosciences, which is developing FGFR inhibitors for cancer, filed plans with the SEC to raise up to $100 million in an initial public offering, as reported in Renaissance Capital. -
FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer
April 17, 2019FDA Approves Balversa (erdafitinib) for the Treatment of Metastatic Bladder Cancer. -
Qiagen launches first FGFR-based cancer diagnostic
April 17, 2019Alongside Janssen’s accelerated approval of Balversa as the first targeted therapy for metastatic bladder cancer, the FDA also greenlighted Qiagen’s companion diagnostic test to ...
Pharma Sources Insight January 2025
